BIOMAT Database Logo BIOMAT Database Logo

Advances in allergen immunotherapy for asthma. 2020

Ioana Agache, and Alexandru Laculiceanu, and Catalina Cojanu, and Daniela Spanu, and Liliana Rogozea
Transylvania University, Faculty of Medicine.

Allergen immunotherapy (AIT) is a well-known disease-modifying intervention for allergic diseases. Its benefit in allergic asthma, ranging from prevention to facilitating asthma control, is yet to be clarified. In 2017, following several well-designed randomised controlled trials (RCTs) with house-dust mites (HDM) sublingual (SLIT) tablets in asthma, global initiative for asthma (GINA) guidelines highlighted the need to treat the allergic component of asthma. In 2019, the European Academy of Allergy and Clinical Immunology published the first comprehensive guidelines for HDM AIT in allergic asthma, formulating separate recommendations for subcutaneous, SLIT drops, and SLIT tablets. Significant steps were undertaken in understanding the mechanisms of allergic asthma, facilitating the stratified approach for selecting responders and in translating the immune-modulation effect in achieving long-term control of the chronic inflammation in asthma. Currently existing guidelines recommend AIT as a therapeutic option in controlled or partially controlled HDM allergic asthma. Limited data are available for pollen, molds and pets, as well as for the severe allergic asthma population. The challenge for the future research will be to clarify the subendotypes of allergic asthma responding to AIT, the mechanisms facilitating its' preventive and disease-modifying effect, the optimal duration of the treatment, and route of administration.

UI MeSH Term Description Entries
D003888 Desensitization, Immunologic Immunosuppression by the administration of increasing doses of antigen. Though the exact mechanism is not clear, the therapy results in an increase in serum levels of allergen-specific IMMUNOGLOBULIN G, suppression of specific IgE, and an increase in suppressor T-cell activity. Allergen Immunotherapy,Allergy Shots,Hyposensitization Therapy,Immunotherapy, Allergen,Venom Immunotherapy,Immunologic Desensitization,Therapy, Hyposensitization,Allergen Immunotherapies,Allergy Shot,Desensitizations, Immunologic,Hyposensitization Therapies,Immunologic Desensitizations,Immunotherapy, Venom,Shot, Allergy,Venom Immunotherapies
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D016032 Randomized Controlled Trials as Topic Works about clinical trials that involve at least one test treatment and one control treatment, concurrent enrollment and follow-up of the test- and control-treated groups, and in which the treatments to be administered are selected by a random process, such as the use of a random-numbers table. Clinical Trials, Randomized,Controlled Clinical Trials, Randomized,Trials, Randomized Clinical
D017410 Practice Guidelines as Topic Works about directions or principles presenting current or future rules of policy for assisting health care practitioners in patient care decisions regarding diagnosis, therapy, or related clinical circumstances. The guidelines may be developed by government agencies at any level, institutions, professional societies, governing boards, or by the convening of expert panels. The guidelines form a basis for the evaluation of all aspects of health care and delivery. Clinical Guidelines as Topic,Best Practices,Best Practice
D039741 Antigens, Dermatophagoides Antigens from the house dust mites (DERMATOPHAGOIDES), mainly D. farinae and D. pteronyssinus. They are proteins, found in mite feces or mite extracts, that can cause ASTHMA and other allergic diseases such as perennial rhinitis (RHINITIS, ALLERGIC, PERENNIAL) and atopic dermatitis (DERMATITIS, ATOPIC). More than 11 groups of Dermatophagoides ALLERGENS have been defined. Group I allergens, such as Der f I and Der p I from the above two species, are among the strongest mite immunogens in humans. Antigens, Dermatophagoides farinae,Antigens, Dermatophagoides pteronyssinus,House Dust Mite Antigens,Allergens, House Dust Mites,Antigens, House Dust Mites,Dermatophagoides Allergens,Dermatophagoides farinae Allergens,Dermatophagoides pteronyssinus Allergens,Norisen,Pharmalgen,Dermatophagoides Antigens,Dermatophagoides farinae Antigens,Dermatophagoides pteronyssinus Antigens
D065631 Rhinitis, Allergic An inflammation of the NASAL MUCOSA triggered by ALLERGENS. Allergic Rhinitis,Allergic Rhinitides,Rhinitides, Allergic

Related Publications

Ioana Agache, and Alexandru Laculiceanu, and Catalina Cojanu, and Daniela Spanu, and Liliana Rogozea
Advances in allergen immunotherapy as a treatment of asthma.
December 2019, Expert review of respiratory medicine,
Ioana Agache, and Alexandru Laculiceanu, and Catalina Cojanu, and Daniela Spanu, and Liliana Rogozea
Allergen immunotherapy for asthma.
January 2003, The Cochrane database of systematic reviews,
Ioana Agache, and Alexandru Laculiceanu, and Catalina Cojanu, and Daniela Spanu, and Liliana Rogozea
Allergen immunotherapy for asthma.
January 2000, The Cochrane database of systematic reviews,
Ioana Agache, and Alexandru Laculiceanu, and Catalina Cojanu, and Daniela Spanu, and Liliana Rogozea
[ALLERGEN IMMUNOTHERAPY FOR ASTHMA].
January 2022, Arerugi = [Allergy],
Ioana Agache, and Alexandru Laculiceanu, and Catalina Cojanu, and Daniela Spanu, and Liliana Rogozea
Allergen Immunotherapy for Asthma.
January 2024, The journal of allergy and clinical immunology. In practice,
Ioana Agache, and Alexandru Laculiceanu, and Catalina Cojanu, and Daniela Spanu, and Liliana Rogozea
Injection allergen immunotherapy for asthma.
August 2010, The Cochrane database of systematic reviews,
Ioana Agache, and Alexandru Laculiceanu, and Catalina Cojanu, and Daniela Spanu, and Liliana Rogozea
Allergen immunotherapy for allergic asthma.
January 2024, Allergologie select,
Ioana Agache, and Alexandru Laculiceanu, and Catalina Cojanu, and Daniela Spanu, and Liliana Rogozea
Allergen Immunotherapy in Asthma.
October 2021, Pathogens (Basel, Switzerland),
Ioana Agache, and Alexandru Laculiceanu, and Catalina Cojanu, and Daniela Spanu, and Liliana Rogozea
[Allergen-immunotherapy in asthma].
January 2008, Arerugi = [Allergy],
Ioana Agache, and Alexandru Laculiceanu, and Catalina Cojanu, and Daniela Spanu, and Liliana Rogozea
Advances in allergen-specific immunotherapy.
April 2005, Expert opinion on biological therapy,
Copied contents to your clipboard!